We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





IL-6 Severity Triage Test Identifies Severe Inflammatory Response in Patients with Confirmed COVID-19 Illness

By LabMedica International staff writers
Posted on 02 Apr 2021
Print article
Illustration
Illustration
A new test has been designed to assist in identifying severe inflammatory response in patients with confirmed COVID-19 illness.

SQI Diagnostics, Inc. (Toronto, ON, Canada) has submitted its fully completed clinical and analytical data package to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) of its RALI-Dx IL-6 Severity Triage Test. The FDA will review the application under its pre-emergency use authorization (PEUA) process before a definitive EUA review. Subject to the acceptance of an EUA, the RALI-Dx IL-6 Severity Triage Test is intended to be utilized by hospital emergency departments and labs to assist clinicians in identifying severe inflammatory response in patients with confirmed COVID-19 illness to aid in determining the risk of intubation with mechanical ventilation.

The RALI-Dx IL-6 Severity Triage Test helps clinicians identify which patients with SARS-CoV-2 will have a severe inflammatory response and should be admitted to the hospital to aid in determining the risk of intubation with mechanical ventilation. The test measures the critical biomarker IL-6 which plays a key role in the cytokine storm phase of COVID-19. The RALI-Dx IL-6 Severity Triage Test delivers results from the lab in about 50 minutes.

"Our priority is to help address this global health emergency," said Mr. Robert L. Chioini, CEO of SQI. "The development and advancement of a test to help identify and determine which COVID-19 patients are at risk of a severe adverse respiratory event is one of our highest priorities in helping combat this expanding health emergency. We think the RALI-Dx IL-6 Severity Triage Test is an important risk assessment tool that can help manage the care of hospitalized COVID-19 patients and the overflow of hospital admissions."

Related Links:
SQI Diagnostics, Inc.

Gold Supplier
SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
New
Molecular Diagnostics Integrated System
SENTiNAT 200
SARS-CoV-2 Antigen Test
ESPLINE SARS-CoV-2 Antigen Test

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.